SCHEMBL4868587

SCHEMBL4868587

COc1cc(Cl)cc(C(=O)O)c1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C4 P17516 1/20 0.58
AKR1C3 P42330 1/20 0.58
AKR1C2 P52895 1/20 0.58
AKR1C1 Q04828 1/20 0.58
KDM4E B2RXH2 3/20 0.58
ERN1 O75460 2/20 0.54
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA12 O43570 1/20 0.53
CA3 P07451 1/20 0.53
PKM P14618 1/20 0.53
CA4 P22748 1/20 0.53
CA6 P23280 1/20 0.53
CA5A P35218 1/20 0.53
CA7 P43166 1/20 0.53
CA9 Q16790 1/20 0.53
CA14 Q9ULX7 1/20 0.53
CA5B Q9Y2D0 1/20 0.53
ALDH1A1 P00352 4/20 0.53
HPGD P15428 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325887 0.85 ERN1 (0.54) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL12316477 0.85 ERN1 (0.54) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL6331461 0.84 ERN1 (0.53) KDM4EERN1CA1CA2CA12
SCHEMBL12316453 0.84 ERN1 (0.53) KDM4EERN1CA1CA2CA12
SCHEMBL16147373 0.82 AKR1C4 (0.55) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL10355676 0.81 KDM4E (0.71) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL18677519 0.81 PKM (0.53) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL15513877 0.81 PKM (0.57) KDM4EERN1CA1CA2CA12
SCHEMBL953480 0.80 KDM4E (0.56) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL1541991 0.80 ERN1 (0.64) KDM4EERN1CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4583870-A2 MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER Mito Biopharma, LLC (US) 2025-07-16 EP disclosed
WO-2024054766-A2 MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER MITO BIOPHARMA, LLC (US) 2024-03-14 WO disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-A2 COMT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-06 EP disclosed
US-20050245520-A1 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors DODIC NERINA 2005-11-03 US disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition F. HOFFMANN-LA ROCHE AG (CH) 2005-06-23 US disclosed
US-20050124664-A1 Urea thiadiazole inhibitors of plasminogen activator inhibior-1 BRISTOL-MYERS SQUIBB CO. 2005-06-09 US disclosed
US-20050050587-A1 Inducers of plant disease resistance VALENT BIOSCIENCES CORPORATION 2005-03-03 US disclosed
WO-1996017630-A9 SUBSTITUTED BENZAMIDES AND RADIOLIGAND ANALOGS AND METHODS OF USE 1996-08-08 WO disclosed
WO-1996017630-A1 SUBSTITUTED BENZAMIDES AND RADIOLIGAND ANALOGS AND METHODS OF USE VANDERBILT UNIVERSITY (US) 1996-06-13 WO disclosed
EP-0083737-A1 N-azabicycloalkane benzamides, process for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1983-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245520-A1 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors SMAD2, SMAD3, ALK AKR1C4 2733/4885AKR1C3 2245/4885AKR1C2 2302/4885
US-20050124664-A1 Urea thiadiazole inhibitors of plasminogen activator inhibior-1 SERPINE1, SERPINC1, SERPINB1 AKR1C4 374/4885AKR1C3 270/4885AKR1C2 530/4885
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition COMT, MAOB, TPH1 AKR1C4 269/4885AKR1C3 240/4885AKR1C2 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.